Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
| Revenue (Most Recent Fiscal Year) | $15.85B |
| Net Income (Most Recent Fiscal Year) | $-559.00M |
| PE Ratio (Current Year Earnings Estimate) | 5.61 |
| PE Ratio (Trailing 12 Months) | 5.17 |
| PEG Ratio (Long Term Growth Estimate) | 1.53 |
| Price to Sales Ratio (Trailing 12 Months) | 0.90 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.76 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.63 |
| Pre-Tax Margin (Trailing 12 Months) | -3.94% |
| Net Margin (Trailing 12 Months) | -3.33% |
| Return on Equity (Trailing 12 Months) | 34.90% |
| Return on Assets (Trailing 12 Months) | 6.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.23 |
| Inventory Turnover (Trailing 12 Months) | 2.01 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.25 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.98 |
| Earnings per Share (Most Recent Fiscal Year) | $2.46 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.47 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 1.12B |
| Free Float | 1.11B |
| Market Capitalization | $14.33B |
| Average Volume (Last 20 Days) | 8.55M |
| Beta (Past 60 Months) | 1.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.62% |
| Percentage Held By Institutions (Latest 13F Reports) | 54.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |